Carna Biosciences, Inc. (TYO:4572)

Japan · Delayed Price · Currency is JPY

409.00

-5.00 (-1.21%)

Oct 6, 2026, 3:30 PM JST

Market Cap	8.82B +119.9%
Revenue (ttm)	729.00M +27.4%
Net Income	-2.15B
EPS	-111.33
Shares Out	21.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	454,300
Open	420.00
Previous Close	414.00
Day's Range	397.00 - 422.00
52-Week Range	200.00 - 512.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 61

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4572

Full Company Profile

Financial Performance

In 2025, Carna Biosciences's revenue was 579.00 million, a decrease of -8.96% compared to the previous year's 636.00 million. Losses were -2.17 billion, -0.32% less than in 2024.

Financial Statements